CONTACT INFORMATION FOR INVESTORS
Teresa Whalen, RPh | CEO | twhalen@cytoagents.com | 412-303-1200
PHASE 2 STAGE IMMUNOTHERAPY: RAISING $25M SERIES A
TARGETING HIGH UNMET NEEDS
INFECTIOUS AND NON-INFECTIOUS INDICATIONS
• CAR-T Cell Therapy
• COVID-19
• Vaping Induced Lung Injury
• Influenza
• Traumatic Brain Injury
• Juvenile Idiopathic Arthritis
SERIES A USE OF PROCEEDS
$25M SERIES A: USE OF PROCEEDS
• CAR-T CRS Non Clinical Studies
• CAR-T CRS Clinical Phase 2A
• Phase 2 COVID-19 Trial
• Non Human Primate COVID-19 Studies
• ARDS/Vaping Non Clinical Studies
• Expand Manufacturing Capabilities
• Expand Patent Portfolio
• Expand Strategic Partnerships
INVESTABLE ASSET
• New Chemical Entity to US and Europe
• Established Safety Profile
• Phase 1 Human Clinical Trial Complete 2/2021
• Awarded $3.6M NIH Non-Dilutive Grants
• Cost Effective, Shelf Stable, Broadly Accessible Treatment
• Can be Used as Treatment and Prophylaxis
• Acute and Non-Acute Indications
• Efficacy Regardless of Viral Strain: Ideal Stockpiling Candidate
• Manufacturing Partnership Established
• Strategic Partner CDA Signed to Accelerate FDA Pathway